Technology
1 min read
Multiply Labs is scaling robotics-driven biomanufacturing to industrialize cell therapy production.
The AMW Read
The article updates the player map for Vertical AI (Healthcare/Bio) by demonstrating a high-impact convergence of Robotics (Segment 10) and biomanufacturing to drive significant cost reduction.
NoveltySignificance
Healthcare & Bio · Player MapRobotics · Player Map
Multiply Labs is scaling robotics-driven biomanufacturing to industrialize cell therapy production. By integrating NVIDIA Physical AI and GR00T models, the company has reduced manufacturing costs by 70%, lowering per-dose expenses from $100,000 to approximately $25,000. This automation increases throughput 100-fold per square foot while eliminating human contamination risks. This transition from manual labs to autonomous robotic clusters marks a systemic shift in making life-saving treatments globally accessible. 🧬🤖
